Cargando…
Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment
Non-selective inhibitors of cholinesterases (ChEs) are clinically used for treatment of myasthenia gravis (MG). While being generally safe, they cause numerous adverse effects including induction of hyperactivity of urinary bladder and intestines affecting quality of patients life. In this study we...
Autores principales: | Petrov, Konstantin A., Kharlamova, Alexandra D., Lenina, Oksana A., Nurtdinov, Ayrat R., Sitdykova, Marina E., Ilyin, Victor I., Zueva, Irina V., Nikolsky, Evgeny E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762639/ https://www.ncbi.nlm.nih.gov/pubmed/29321572 http://dx.doi.org/10.1038/s41598-017-18307-9 |
Ejemplares similares
-
Slow-binding reversible inhibitor of acetylcholinesterase with long-lasting action for prophylaxis of organophosphate poisoning
por: Lenina, Oksana A., et al.
Publicado: (2020) -
Balanced modulation of neuromuscular synaptic transmission via M1 and M2 muscarinic receptors during inhibition of cholinesterases
por: Lenina, Oksana A., et al.
Publicado: (2022) -
Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer’s Disease
por: Semenov, Vyacheslav E., et al.
Publicado: (2022) -
Novel Acetylcholinesterase Inhibitors Based on Uracil Moiety for Possible Treatment of Alzheimer Disease
por: Semenov, Vyacheslav E., et al.
Publicado: (2020) -
Autoregulation of Acetylcholine Release and Micro-Pharmacodynamic Mechanisms at Neuromuscular Junction: Selective Acetylcholinesterase Inhibitors for Therapy of Myasthenic Syndromes
por: Petrov, Konstantin A., et al.
Publicado: (2018)